January' 2023
Study published in Journal of Bone and Joint Infection

A study reporting that systemic rifampicin shows accretion to locally implanted hydroxyapatite particles in a rat abdominal muscle pouch model published in Journal of Bone and Joint Infection.

Read More:

December' 2022
Safety study published in Frontiers in Bioengineering and Biotechnology by TERM group

A safety study titled ‘Longitudinal in vivo bio distribution of nano and micro sized hydroxyapatite particles implanted in a bone defect’ has been published on Frontiers in Bioengineering and Biotechnology by TERM group at Lund University.

The study shows locally implanted nano and micro hydroxyapatite particles in a bone defect, do not migrate to the other vital organs in the body, thereby strengthening an apatite based drug delivery system in solid tumors.

Read more via the following link:

December' 2022
Doctoral Thesis

Defended thesis:  Hydroxyapatite – A trojan horse in the delivery of apatite-binding cytostatics in bone cancer — Department of Clinical Sciences, Lund, Faculty of Medicine, Lund University. Yang Liu. 

On Monday the 18th of December 2022 Yang Liu, defended his thesis “Hydroxyapatite – A trojan horse in the delivery of apatite-binding cytostatics in bone cancer” at the Faculty of Medicine, Lund University. 

Yang Liu has been a researcher within the TERM group at the Medical Faculty, Lund University, for four years and during this period co-authored several articles in reputable scientific journals alongside with the work on his dissertation. 

Liu’s thesis describes a new and efficient method to supplement osteosarcoma treatment, with a possible rapid translation potential, using clinically approved constituents. Read more via the following link: 

Hydroxyapatite – A trojan horse in the delivery of apatite-binding cytostatics in bone cancer — Lund University

Study published in Bone Joint Research

TERM group has published a study showing Extended Local Release and Improved Bacterial Eradication by Adding Rifampicin to a Biphasic Ceramic Carrier Containing Gentamicin or Vancomycin published in Bone Joint Research.

TERM group presented their work at the European Orthopedic Research Society and International Combined Orthopedic Research Society joint meeting in Edinburgh, Scotland.

Two presentations and a poster were presented by the TERM group at EORS and International Combined Orthopaedic Research Society joint meeting. 

Talk 1: Enhanced Staphylococcus Aureus Antibiofilm Activity Without Resistance Development By Adding Rifampicin To A Biphasic Ceramic Carrier Containing Gentamicin Or Vancomycin.

Talk 2: A New Method For Improved Mechanical And Biological Fixation Of Fracture Fixation Devices.

Poster: Improved mechanical anchorage of gamma nail lag-screw in osteoporotic bone: A bio-mechanical study.

September' 2022
Invited talk at the Nordic Orthopedic Foundation's annual meeting

Researchers from TERM group gave an invited talk on ‘A New Augmentation Method for Improved Screw Fixation in Fragile Bone With focus on trochanteric fractures’ at the Nordic Orthopedic Foundation’s annual meeting in Vilnius, Lithuania.

April' 2022
Article published by The Medical Faculty at Lund University highlighting our research work in the tumor area

The Medical Faculty at Lund University wrote about our research on a supplement treatment for osteosarcoma by using a bone mineral (hydroxyapatite) as a carrier system, to deliver an already approved cytostatic drug, Doxorubicin, targeted to the mitochondria and using the hydroxyapatite particles for post-operative systemic loading with apatite seeking cytostatic drugs.

Link to the article:

November' 2021
NIRA nominations at the ORS 2022 Annual Meeting

Two researchers from our group, Deepak Raina and Sujeesh Sebastian were nominated for the prestigious New Investigator Recognition Award (NIRA).

The group had submitted 6 abstracts highlighting their work in the area of tumor, fracture fixation and bone infection.

1)A novel method for improved screw fixation in fragile bone.

2) A novel method of in-situ activation of synthetic hydroxyapatite (HA) particles for improved bone-implant integration.

3) Ultra-low dose bone morphogenic protein-2/7 heterodimer delivered via a collagen-HA scaffold for critical femoral defect healing in rats.

4) HA mediated delivery of doxorubicin for efficient intracellular and sustained extracellular drug delivery with improved tumor eradication.

5) A targeted drug delivery approach in deep bone infections using synthetic HA as a recruiting moiety.

6) Evaluation of Injectable Calcium Sulfate/ HA Cement for Augmentation of Pedicle Screws in Osteoporotic Vertebrae: A Cadaver Study

October' 2021
Research grant of 5.2 MSEK awarded by The Swedish Research Council for tumor research

Our group has received a grant of 5.2 MSEK from the Swedish Research Council to further our work in the field of solid tumor. The project is titled ‘Bio-modulation: Targeting bone disease by a Trojan horse. Repurposing old drugs to treat bone cancers’, where we have discovered a novel way of using nano and micro apatite particles as a local target and a carrier for drugs directed at solid tumor. The project will be supported by the Swedish Research Council for a period of 4 years.

June' 2021
Research grant awarded by The Crafoord Foundation

Scientific research grant of  400,000 SEK awarded by Crafoordska Stiftelsen to further our research in the area of bone regeneration.

May' 2021
Stipendium of 150,000 SEK granted by Sten K Johnsons Stiftelse

Stipend granted by Sten K Johnsons Stiftelse for our project titled ‘Can securing the hip be synonymous with securing the future quality of life in the elderly?’

February' 2021
Prof. Magnus Tägil, Deepak Raina and Yang Liu presented their work at ORS annual Meeting 2021 

Prof Magnus Tägil presented a follow up study of patients that underwent treatment for fractures of the hand in one of the largest hand surgery cohorts of 3666 patients. 

Deepak Raina presented his data on the comparison of the bone forming potential of a new osteoinductive protein BMP-2/7 compared to the clinically used BMP-2 demonstrating a significantly higher bone forming response from the new BMP-2/7 protein.

Yang Liu presented data from the tumor project where he demonstrated that an osteoporosis drug zoledronic acid increases the binding of a tumor drug doxorubicin to hydroxyapatite particles and leads to a stronger tumor killing effect in-vitro. 

February' 2021
Research support of NOK 10,000,000 granted by Olav Thon Foundation

Research grant to reduce incidence of re-operation following surgical implants to treat hip fracture in the elderly. The project spans a period of 4 years and receives a total of NOK 10,000,000.

December' 2020
Our study published in Science Advances was highlighted in the media

Our study on developing an novel method by way of combining a bone substitute and drugs to regenerate bone and heal severe fractures, published in Science Advances was highlighted in Sydsvenskan.

November' 2020
Research article in Science Advances

TERM Group in collaboration with colleagues from University Center of Orthopedic, Trauma and Plastic Surgery, Dresden, Germany, demonstrated that a carrier consisting of a powder of calcium sulfate/hydroxyapatite (CaS/HA) mixed with bone active molecules provides an efficient drug delivery platform for critical femoral defect healing in rats.  It was also demonstrated that delivery of rhBMP-2 was necessary for critical defect healing and restoration of mechanical properties, but codelivery of BMP-2 and ZA led to denser and stronger fracture calluses. Together, the CaS/HA biomaterial with rhBMP-2 and/or ZA can potentially be used as an off-the-shelf alternative to autograft bone.

DOI: 10.1126/sciadv. abc1779.

September' 2020
Prof. Lars Lidgren and Sujeesh Sebastian present their work in EORS

Prof. Lars gave a presentation on ‘Bone mineral a drug seeking moiety and a waste dump’ at the 2020 Annual Meeting of the European Orthopaedic Research Society, Izmir.